Prevention of Fractures in Patients with Parkinson's Disease
帕金森病患者骨折的预防
基本信息
- 批准号:10617169
- 负责人:
- 金额:$ 319.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-30 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:AcidsAddressAgeBindingBlindedBone DensityBone remodelingCalciumCessation of lifeClinic VisitsClinicalCommunitiesDataDiagnosisDocumentationEnrollmentEvaluationFoundationsFractureGuidelinesHealth systemHip FracturesHomeInfusion proceduresInstitutional Review BoardsIntravenousMedicalMonitorMovement DisordersNeurologistNursing ResearchOralOsteoporosisParkinson DiseasePatient CarePatientsPharmaceutical PreparationsPlacebo ControlPlacebosPreventionRecovery of FunctionResearch DesignRiskRisk ReductionSpecialistSubgroupSurveysTelemedicineTestingUncertaintyVisitVitamin D supplementationWomanZoledronic Acidbarrier to carebisphosphonatebonebone lossclinical diagnosisdesigndiarieseconomic evaluationefficacy testingefficacy trialexperiencefall riskfallsfollow-upfracture riskhealth economicshigh riskhuman old age (65+)improvedmenmortalitynon-complianceolder patientpelvis fracturepharmacologicpopulation basedpreservationpreventprimary endpointrandomized placebo controlled trialrandomized trialrecruitsafety assessmentscreeningsecondary endpointtreatment response
项目摘要
Patients with Parkinson's disease (PD) have a very high risk of fracture: about 2 to 3-fold increased risk of all
fractures and 4-fold increased risk of hip fracture that may be due in large part to their very high risk of multiple
falls. Compared with other patients who suffer fractures, PD patients have more severe consequences of
fractures: they have twice the risk of dying following hip and pelvic fractures and longer and incomplete
functional recovery, with worsening of Parkinson's disease. Crucially, men and women age 65 or older have a
fracture risk that is so high, that even those with normal bone density (BMD) for age would warrant a therapy
that has been proven to reduce fracture risk in patients with PD.
However, very few PD patients age 65 of older receive a treatment for osteoporosis. There are several major
barriers to treatment of PD patients with drugs for osteoporosis. 1) There is a lack of evidence that treatments
reduce fracture risk in patients with PD whose risk of fractures may be due to multiple and more severe falls. 2)
Standard osteoporosis screening and treatment may also be a barrier. Medical visits to assess fracture risk,
test BMD, prescribe treatment, generally an oral drug, and then follow-up to monitor compliance and response
to treatment, are particularly burdensome for patients with PD. 3) Most patients with PD do not continue taking
oral osteoporosis drugs even for 1 year.
We propose a randomized trial that addresses all of these barriers. 1) We will test the anti-fracture efficacy of
Zoledronic acid (ZA) a very potent bisphosphonate that inhibits bone loss and decreased fracture risk in
women with osteoporosis and patients with hip fractures. 2) We will give ZA intravenously at home without
clinic visits. 3) ZA inhibits bone loss for at least 2 years overcoming noncompliance with oral drugs. We will
enroll 3,500 men and women PD age 65 years or older from large health systems, patient communities, and
referrals from neurologists in the Parkinson's Study Group. A movement disorders specialist will confirm the
diagnosis of PD by telemedicine. We will then provide calcium and vitamin D supplements. A research nurse
will visit the patient at home, check for potential contraindications to ZA and then administer IV ZA or placebo.
We will then follow patients for 2 years to ascertain and confirm fractures.
A successful result may revolutionize the care of patients with PD. It may lead to guidelines promoting
home-based ZA treatment of older PD patients. ZA, rather than oral drugs, would become the 1st line treatment
for patients with PD. The trial would demonstrate that home-based treatment with ZA, without other
assessments, could reach all older PD patients without the need for burdensome medical visits. Thus, a
positive result may lead to treatment of many more PD patients and a substantial reduction in the occurrence
of disabling fractures in patients with PD.
帕金森病(PD)患者骨折的风险非常高:所有患者的风险增加约2至3倍。
骨折和4倍增加髋部骨折的风险,这可能在很大程度上是由于他们非常高的风险,
福尔斯。与其他遭受骨折的患者相比,PD患者有更严重的后果,
骨折:他们在髋部和骨盆骨折后死亡的风险是其他人的两倍,
功能恢复,帕金森病恶化。重要的是,65岁或以上的男性和女性有一个
骨折的风险是如此之高,即使是那些正常的骨密度(BMD)的年龄将保证治疗
已被证明可以降低PD患者的骨折风险。
然而,很少有65岁以上的PD患者接受骨质疏松症的治疗。有几大
使用骨质疏松症药物治疗PD患者的障碍。1)没有证据表明治疗
降低PD患者的骨折风险,这些患者的骨折风险可能是由于多次和更严重的福尔斯跌倒所致。(二)、
标准的骨质疏松症筛查和治疗也可能是一个障碍。进行医疗访问以评估骨折风险,
测试骨密度,开处方治疗,通常是口服药物,然后随访以监测依从性和反应
对于PD患者来说,治疗尤其困难。3)大多数PD患者不继续服用
口服骨质疏松药物甚至1年。
我们提出了一个随机试验,解决所有这些障碍。1)我们将测试
唑来膦酸(ZA)是一种非常有效的双膦酸盐,可抑制骨丢失并降低骨折风险,
骨质疏松症妇女和髋部骨折患者。2)我们将在家中静脉注射ZA,
诊所访问。3)ZA抑制骨丢失至少2年,克服口服药物的不依从性。我们将
从大型卫生系统、患者社区招募3,500名65岁或以上的男性和女性PD,
帕金森病研究小组的神经科医生的推荐。运动障碍专家会确认
通过远程医疗诊断PD。然后我们将提供钙和维生素D补充剂。研究护士
将在家中访问患者,检查ZA的潜在禁忌症,然后IV ZA或安慰剂给药。
然后,我们将对患者进行为期2年的随访,以确定并确认骨折。
一个成功的结果可能会彻底改变PD患者的护理。这可能会导致指导方针,
老年PD患者的家庭ZA治疗。ZA,而不是口服药物,将成为一线治疗
对于PD患者。该试验将证明,在没有其他药物的情况下,
评估,可以达到所有老年PD患者,而不需要繁琐的医疗访问。因此
阳性结果可能会导致更多的PD患者接受治疗,并大幅降低PD的发生率。
残疾性骨折的风险
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEVEN RON CUMMINGS其他文献
STEVEN RON CUMMINGS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEVEN RON CUMMINGS', 18)}}的其他基金
Study of Muscle, Mobility and Aging (SOMMA)
肌肉、活动能力和衰老研究 (SOMMA)
- 批准号:
10170192 - 财政年份:2018
- 资助金额:
$ 319.24万 - 项目类别:
Study of Muscle, Mobility and Aging: SOMMA2
肌肉、活动能力和衰老研究:SOMMA2
- 批准号:
10913728 - 财政年份:2018
- 资助金额:
$ 319.24万 - 项目类别:
Study of Muscle, Mobility and Aging (SOMMA)
肌肉、活动能力和衰老研究 (SOMMA)
- 批准号:
10441623 - 财政年份:2018
- 资助金额:
$ 319.24万 - 项目类别:
Study of Muscle, Mobility and Aging (SOMMA)
肌肉、活动能力和衰老研究 (SOMMA)
- 批准号:
10015194 - 财政年份:2018
- 资助金额:
$ 319.24万 - 项目类别:
Study of Muscle, Mobility and Aging (SOMMA)
肌肉、活动能力和衰老研究 (SOMMA)
- 批准号:
10652212 - 财政年份:2018
- 资助金额:
$ 319.24万 - 项目类别:
Comprehensive Evaluation of Aging-Related Clinical Outcomes and Geroproteins
衰老相关临床结果和Gero蛋白的综合评价
- 批准号:
9519838 - 财政年份:2016
- 资助金额:
$ 319.24万 - 项目类别:
Comprehensive Evaluation of Aging-Related Clinical Outcomes and Geroproteins
衰老相关临床结果和Gero蛋白的综合评价
- 批准号:
9279037 - 财政年份:2016
- 资助金额:
$ 319.24万 - 项目类别:
Comprehensive Evaluation of Aging-Related Clinical Outcomes and Geroproteins - SUPPLEMENT
衰老相关临床结果和老年蛋白的综合评估 - 补充材料
- 批准号:
9445352 - 财政年份:2016
- 资助金额:
$ 319.24万 - 项目类别:
Comprehensive Evaluation of Aging-Related Clinical Outcomes and Geroproteins
衰老相关临床结果和Gero蛋白的综合评价
- 批准号:
9119555 - 财政年份:2016
- 资助金额:
$ 319.24万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 319.24万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 319.24万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 319.24万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 319.24万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 319.24万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 319.24万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 319.24万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 319.24万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 319.24万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 319.24万 - 项目类别:
Research Grant